


COPENDING APPLICATIONS

§ 1.98(a)(2) Content of information disclosure statement: Section 1.98(a)(2)(iii) requires submission of copies of U.S. patent applications that are being cited in IDS statements.

§ 1.98(d)(2) If a U.S. application was cited in an IDS prior to the effective date of the change to § 1.98(a)(2) (now requiring a copy of the cited application) but a copy of the cited application was not supplied, as was permissible under the former rule, a copy of the cited application must be supplied if cited in any continuing application where the citation is made after the effective date of the changes to §§ 1.98(a) and (d).



<u>Attv. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
7996P	60/193,846	deLong et al	3/31/2000
7998P	60/193,645	deLong et al	3/31/2000
7999P	60/193,844	deLong et al	3/31/2000
8191	09/633,180	deLong	8/4/2000

Continued

Ex: L. Channavajjala

4/17/02

LIST OF DOCUMENTS CITED BY APPLICANTS (Use several sheets if necessary)	ATTY. DOCKET NO. 7997	SERIAL NO. not assigned
APPLICANT DeLong		
FILING DATE 1/31/2001	GROUP not assigned	

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US 3,435,053	3/25/69	Beal et al	260/345.2	-	
	US 3,524,867	8/18/70	Beal et al	260/345.2	-	
	US 3,598,858	8/10/71	Bergstrom et al	260/488.0	-	
	US 3,661,216	9/12/72	Bergstrom et al	260/488 R	260/488R	
	US 3,708,789	12/18/72	Bergstrom et al	260/488 D	260/211R	
	US 3,776,938	12/4/73	Bergstrom et al	260/488 D	-	
	US 3,776,939	12/4/73	Bergstrom et al	260/488 D	-	
	US 3,839,409	10/1/74	Bergstrom et al	260/488 D	-	
	US 3,852,337	12/3/74	Bergstrom et al	260/488R	260/410	
	US 3,882,241	5/6/75	Pharries, BB	424/305	424/318	
	US 3,882,245	5/6/75	DuCharme, DW	424/318	424/305	
	US 3,896,156	7/22/75	Beal et al	260/488D	260/211	
	US 3,928,588	12/23/75	Robert, A	424/234	424/273	
	US 3,968,792	8/28/76	Hayashi et al	260/488D	260/210R	
	US 3,984,455	10/5/76	Beal et al	260/488D	260/247.2R	
	US 4,011,262	3/8/77	Hess et al	260/520B	260/240R	
	US 4,024,178	5/17/77	Bindra et al	260/473A	260/240R	
	US 4,081,871	12/6/77	Beck et al	260/514D	260/343.3R	
	US 4,073,934	2/14/78	Skuballa et al	424/305	260/295R	
	US 4,089,885	5/16/78	Hushands, GEM	260/448.8R	260/514D	
	US 4,123,441	10/31/78	Johnson, RA	260/345.2	424/283	
	US 4,128,720	12/5/78	Hayashi et al	560/8	260/327M	
	US 4,158,887	6/19/79	Axon, UF	260/413	260/346.22	
	US 4,225,507	8/30/80	Sh, JC	260/346.22	260/345.2	
	US 4,225,508	9/30/80	Sh, JC	260/346.22	260/345.2	
	US 4,284,846	8/18/81	Vorbruggen et al	424/305	260/340.5P	
	US 4,489,082	12/18/84	Vorbruggen et al	424/304	260/345.7P	
	US 4,499,293	2/12/85	Johnson et al	549/485	548/252	
	US 4,821,100	11/4/86	Lund et al	514/573	514/155	
	US 4,704,388	11/3/87	Mueller, RA	514/211	540/547	
	US 4,889,845	12/26/89	Ritter et al	514/83	514/573	
	US 5,063,057	11/5/91	Spellman et al	424/401	208/528	
	US 5,219,885	8/15/93	Frolich et al	514/530	-	
	US 5,280,018	1/18/94	Ritter et al	514/83	424/47	
	US 5,340,813	8/23/94	Klein et al	514/263	544/272	
	US 5,422,371	6/6/95	Liao et al	514/580	514/703	
	US 5,464,868	11/7/95	Frolich et al	514/530	-	
	US 5,508,303	4/16/96	Isogaya, et al	514/468	549/458	
	US 5,516,652	5/14/96	Abramovitz et al	435/69.1	435/240.1	
	US 5,567,079	10/22/96	Felder, A	405/80	405/74	
	US 5,576,315	11/19/96	Hallinan et al	514/211	540/547	
	US 5,578,640	11/26/96	Hanson, WR	514/530	514/573	
	US 5,578,643	11/26/96	Hanson, WR	514/573	514/530	
	US 5,605,814	2/25/97	Abramovitz et al	435/69.1	435/252.3	
	US 5,605,931	2/25/97	Hanson, WR	514/530	514/573	
	US 5,658,897	8/17/97	Burk, RM	514/118	546/22	
	US 5,663,203	9/2/97	Ekerdt et al	514/572	514/573	
	US 5,670,506	9/23/97	Leigh et al	514/258	514/263	

Ex 1 L. Channavajjala

4/17/02

	US 5,681,850	10/28/97	Frolich et al	514/530	-	
	US 5,703,108	12/30/97	Cameron et al	514/382	514/304	
	US 5,719,140	2/17/98	Chandrakumar et al	514/211	540/547	
	US 5,759,789	6/2/98	Abramovitz et al	435/7.21	435/69.1	
	US 5,770,759	8/23/98	U no et al	560/53	560/121	
	US 5,792,851	8/11/98	Schuster et al	536/23.5	435/69.1	
	US 5,840,847	11/24/98	Abramovitz et al	530/350	435/69.1	
	US 5,834,498	11/10/98	Burk, RM	514/445	514/438	
	US 5,869,281	2/9/1999	Abramovitz et al	435/69.1	435/252.3	
	US 5,877,211	3/2/1999	Woodward	514/530	514/573	
	US 5,885,766	3/23/1999	Mahe et al	435/1.1	435/29	
	US 5,885,974	3/23/1999	Danielov, MM	514/109	514/103	
	US 5,889,052	3/30/1999	Klimko, et al	514/530	514/573	
	US 5,892,099	4/6/1999	Maruyama, et al	560/121	560/15	
	US 5,958,723	8/28/1999	Abramovitz et al	435/69.1	536/23.5	
	US 5,972,965	10/26/99	Taniguchi et al	514/326	514/374	
	US 5,973,002	10/26/99	Frolich et al	514/530	514/530	
	US 5,977,173	11/2/99	Woo et al	514/530	514/562	
	US 5,985,597	11/16/99	Ford-Hutchinson et al	435/69.1	435/252.3	
	US 5,990,346	11/23/99	Kataoka et al	562/503	549/422	
	US 5,994,397	11/30/99	Selliah et al	514/473	549/475	
	US 6,013,823	1/11/00	Mamarella et al	556/443	-	
	US 6,025,375	2/15/00	Taniguchi et al	514/374	548/236	
	US 6,025,382	2/14/00	Selliah et al	514/473	549/475	
	US 6,030,959	2/29/00	Tremont et al	514/63	556/418	
	US 6,030,999	2/29/00	Stjemachantz et al	514/530	-	
	US 6,031,001	2/29/00	Stjemachantz et al	514/573	-	
	US 6,031,079	2/29/00	Ford-Hutchinson et al	530/350	435/69.1	
	US 6,037,364	3/14/00	Burk, RM	514/438	514/461	
	US 6,037,368	3/14/00	Podos et al	514/530	514/573	
	US 6,043,264	3/28/00	Ohtake et al	514/374	514/444	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
	BE 746615	7/31/70	Belgium	A61K		X	
	DE 1617477	1/8/70	Germany	A61K		X	
	DE 2460990	12/21/74	Germany	C07C	177/00	X	
	EP 249194	6/9/86	EPO	A61K	31/557		
	EP 648488	10/13/83	EPO	A61K	31/00	X	
	EP 911321	4/28/89	EPO	C07C	311/13		
	EP 925787	6/30/89	EPO	A61K	31/557		
	EP 970897	9/16/89	EPO	A61K	31/557		
	EP 947500	10/6/89	EPO	C07C	233/25		
	EP 1008588	2/10/88	EPO	C07C	405/00		
	EP 1016660	9/07/98	EPO	C07D	208/42		
	FR 2,108,027	9/27/71	FRANCE	A61K	7/00	X	
	FR 2,730,811	2/27/85	FRANCE	G01N	33/48	X	
	GB 1251750	10/27/71	GREAT BRITAIN	C07C	61/32		
	GB 1285371	8/16/72	GREAT BRITAIN	A61K	27/00		
	GB 1285372	8/16/72	GREAT BRITAIN	C07C	61/32		
	GB 1456512	11/24/76	GREAT BRITAIN	C07C	177/00		
	GB 1456513	11/24/76	GREAT BRITAIN	C07D	307/93		
	GB 1456514	11/24/76	GREAT BRITAIN	C07F	9/40		
	GB 2048254	12/10/80	UNITED KINGDOM	C07C	177/10		
	GB 2330307	4/21/89	UNITED KINGDOM	A61K	31/557		
	JP 3-83,925	4/9/81	JAPAN	A61K	31/557	X	
	JP 3-83,926	4/9/81	JAPAN	A61K	31/557	X	
	JP 4-300,833	10/23/92	JAPAN	A61K	31/557	X	
	JP 9-295,921	11/18/97	JAPAN	A61K	7/06	X	

Ex: L Channasjale

4/17/02

	JP 10-287,532	10/27/98	JAPAN	A61K	7/08	X	
	JP 49-101,356	9/25/74	JAPAN	16C86	--	X	
	JP 49-102,647	9/27/74	JAPAN	16C88	--	X	
	JP 61-218,510	9/29/86	JAPAN	A61K	7/08	X	
	WO 00/2450	1/20/2000	PCT	A01N	37/08		
	WO 00/3736	1/27/2000	PCT	A61K	47/44		
	WO 00/3980	1/27/2000	PCT	C07C	405/00		
	WO 00/4888	2/3/2000	PCT	A61K	31/215		
	WO 00/4899	2/3/2000	PCT	A61K	31/215		
	WO 00/9557	2/24/2000	PCT	C07C	14/47		
	WO 00/13664	3/16/2000	PCT	A61K	47/38		
	WO 00/15608	3/23/2000	PCT	C07C	405/00		
	WO 00/16780	3/30/2000	PCT	A61K	31/00		
	WO 86/00616	1/30/1986	PCT	C07D	239/02		
	WO 84/08585	4/28/84	PCT	A61K	31/557		
	WO 95/00562	1/5/95	PCT	C07K	13/00		
	WO 95/11003	4/27/95	PCT	A61K	7/42		
	WO 95/11033	4/27/95	PCT	A61K	33/24		
	WO 95/19964	7/27/95	PCT	C07C	405/00		
	WO 98/10407	4/11/96	PCT	A61K	31/557		
	WO 97/08049	3/13/97	PCT	A61K	31/557		
	WO 97/15319	5/1/97	PCT	A61K	38/18		
	WO 97/23223	7/3/97	PCT	A61K	31/557		
	WO 97/23225	7/3/97	PCT	A61K	31/557		
	WO 97/23226	7/3/97	PCT	A61K	31/557		
	WO 97/28735	8/21/97	PCT	A61K	7/42		
	WO 97/39754	10/30/97	PCT	A61K	31/557		
	WO 98/00100	1/8/98	PCT	A61K	7/42		
	WO 98/12175	--	PCT	C07C	405/00		
	WO 98/13016	4/02/98	PCT	A61K	7/42		
	WO 98/19680	5/14/98	PCT	A61K	31/557		
	WO 98/20880	5/22/98	PCT	A61K	31/557		
	WO 98/20881	5/22/98	PCT	A61K	31/557		
	WO 98/21180	5/22/98	PCT	C07C	405/00		
	WO 98/21181	5/22/98	PCT	C07C	405/00		
	WO 98/21182	5/22/98	PCT	C07C	405/00		
	WO 98/27976	7/2/98	PCT	A61K	31/18		
	WO 98/28264	7/2/98	PCT	C07C	311/08		
	WO 98/33497	8/6/98	PCT	A61K	31/215		
	WO 98/39283	9/11/98	PCT	C07C	405/00		
	WO 98/50024	11/12/98	PCT	A61K	31/215		
	WO 98/53809	12/3/98	PCT	A61K	31/215		
	WO 98/57830	12/23/98	PCT	C07C	405/00		
	WO 98/57942	12/23/98	PCT	C07D	307/20		
	WO 98/58911	12/30/98	PCT	C07C	405/00		
	WO 99/02165	1/21/99	PCT	A61K	31/557		
	WO 99/12550	3/18/99	PCT	A61K	31/557		
	WO 99/12551	3/18/99	PCT	A61K	31/557		
	WO 99/12895	3/18/99	PCT	C07C	405/00		
	WO 99/12896	3/18/99	PCT	C07C	405/00		
	WO 99/12897	3/18/99	PCT	C07C	405/00		
	WO 99/12898	3/18/99	PCT	C07C	405/00		
	WO 99/12898	3/18/99	PCT	C07C	405/00		
	WO 99/19300	4/22/99	PCT	C07D	213/71		
	WO 99/21562	5/6/99	PCT	A61K	31/557		
	WO 99/22731	5/14/99	PCT	A61K	31/44		
	WO 99/25357	5/27/99	PCT	A61K	31/557		
	WO 99/25358	5/27/99	PCT	A61K	31/557		
	WO 99/30675	6/24/99	PCT	A61K	7/08		
	WO 99/30718	6/24/99	PCT	A61K	31/557		
	WO 99/32441	7/1/99	PCT	C07C	405/00		
	WO 99/32640	7/1/99	PCT	C12N	15/62		

L. Chamarajala

4/17/02

	WO 99/32841	7/1/99	PCT	C12N	15/80		
	WO 99/33794	7/8/99	PCT	C07C	405/00		
	WO 99/47497	9/23/99	PCT	C07C	315/00		
	WO 99/50241	10/7/99	PCT	C07C	405/00		
	WO 99/50242	10/7/99	PCT	C07C	405/00		
	WO 99/61029	12/2/99	PCT	A61K	31/557		
	WO 99/64621	12/16/99	PCT	C12Q	1/25		
	WO 99/65303	12/23/99	PCT	A01N	37/08		
	WO 99/65527	12/23/99	PCT	A61K	47/10		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	DeLong MA Prostaglandin receptor ligands: Recent patent activity. <i>Drugs</i> 2000 3(9): 1039-1052
	Negishi, M.; Sugimoto, Y.; Ichikawa, A.; Molecular mechanisms of diverse actions of prostanoid receptors. <i>Biochimica et Biophysica Acta</i> 1259 1995 109-120.
	Collins, PW; Djuric SW; Synthesis of therapeutically useful prostaglandin and prostacyclin analogs <i>Chem. Rev.</i> 1993 93 1533-1584.
	Coleman RA, Kennedy I, Humphrey PPA, Bunce K, Lumley P Prostanoids and their receptors. <i>Comprehensive Medicinal Chemistry</i> , Vol. 3; Membranes and Receptors. 1990 643-714
Unable to obtain reference	Coleman RA, Smith WL, Narumiya S <i>Pharmacol. Rev.</i> 1994 46 205-229.
	Albert Alm, MD The Potential of prostaglandin derivatives in glaucoma therapy; Prostaglandins and derivatives <i>Current Opinion in Ophthalmology</i> 1993 4(11) 44-50.
	Coleman RA, Smith WL, Narumiya S Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes <i>Pharmacological Reviews</i> 1994 46(2) 205-229.
	Kiryama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells <i>British Journal of Pharmacology</i> 1997 (122) 217-224.
	Funk CD, Furci L, Fitzgerald GA, Cloning and expression of a cDNA for the human prostaglandin E receptor EP ₁ subtype <i>Journal of Biological Chemistry</i> 1993 (268) 26767-26772.
	Abramovitz M, Bole Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM and Grygorczyk R Cloning and expression of a cDNA for the human prostanoid FP receptor <i>Journal of Biological Chemistry</i> 1994 269 2832-2838.
	Ichikawa EA, Sugimoto Y, Negishi M Molecular aspects of the structures and functions of the prostaglandin E receptors <i>Journal of Lipid Mediators Cell Signalling</i> 14 1996 63-87.
	Krauss AHP, Woodward DF, Gibson LL, Protzman CE, Williams LS, Burk RM, Gac TS, Roof MB, Abbas F, Marshall K, Senior J Evidence for human thromboxane receptor heterogeneity using a novel series of 8,11-cyclic carbonates derivatives of prostaglandin-F ₂ -alpha <i>British Journal of Pharmacology</i> 1996 117(6) 1171-1180.
	Corsini A, Folco GC, Fumagalli R, Nicolis S, Noe MA, Olive D (5Z)-Carbacyclin discriminates between prostacyclin receptors coupled to adenylyl cyclase in vascular smooth muscle and platelets <i>British Journal of Pharmacology</i> 1997 90 255-261.
Unable to obtain reference	Woodward DF, Gil DW, Chen J, Burk RM, Kedzie KM, Krauss AHP Emerging evidence for additional prostanoid receptor subtypes <i>Cur. Top. Pharmacol.</i> 1998 4 153-162.
	Woodward DF, Madhu C, Rix P, Khariamb A Studies on the ocular effects of a pharmacologically novel agent prostaglandin F ₂ alpha 1-OCH ₃ (AGN 191129) <i>N-S Archives of Pharmacology</i> 1996 358 (1). P1713
	Orlicky DJ Negative regulatory activity of a prostaglandin F ₂ receptor associated protein (FPRP) <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> 1996 54(4) 247-259.

Ex: L. Channavajjala

4/17/02

	Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, Persson B Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG)-A widespread protein superfamily <i>Am. J. Resp. Crit. Care Med.</i> 2000 (161) S20-S24.
	Abramovitz M, Adam M, Bole Y, Carriere MC, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gosselin Y, Ruel R, Juteau H, Labelle M, Ouhet N, Metters KM The utilization of recombinant prostanoic receptors to determine the affinities and selectivities of prostaglandins and related analogs <i>Biochimica et Biophysica Acta</i> 2000 1483 (2) 285-293.
	Ruel R, Lacombe P, Abramovitz M, Godbout C, Lamontagne S, Rochette C, Sawyer N, Stocco R, Tremblay NM, Metters KM, Labelle M New class of biphenylene dibenzazocinones as potent ligands for the human EP ₁ prostanoic receptor <i>Bioorganic & Medicinal Chemistry Letters</i> . 1999 (9) 2699-2704.
	Hallinan EA, Hagen TJ, Tsymlalov S, Huss RK, Lee AC, Staplefield A, Savage MA Aminoacyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE ₂ antagonist, and its analogs <i>J. Med. Chem.</i> 1996 39 809-813
Unable to obtain reference	Pharmaprojects-No.6321
	Maruyama T, Koketsu M, Yamamoto H, Yamamoto K, Yamamoto L T, Hayashida K I, Ohuchida S, Kondo K EP ₁ receptor antagonists suppress tactile allodynia in rats <i>Prostaglandins Lipid Mediat.</i> 1999 59 217.
Unable to obtain reference	ADIS, ADISINSIGHT: ZD-6416-Mar-27-2000.
	Ueda K, Saito A, Nakano H, Aoshima M, Yokota M, Murakami R, Iwata T Brief clinical and laboratory observations: Cortical hyperostosis following long-term administration of prostaglandin E ₁ in infants with cyanotic congenital heart disease <i>The Journal of Pediatrics</i> 1989 87 834-836.
	Shih MS, Norrdin RW PGE ₂ induces regional remodeling changes in Haversian envelope: A histomorphometric study of fractured ribs in beagles <i>Bone and Mineral</i> 1996 (1) 227-234.
	Mori S, Jee WSS, Li XJ, Chan S, Kimmel DB Effects of prostaglandin E ₂ on production of new cancellous bone in the axial skeleton of ovariectomized rats <i>Bone</i> 1999 (11) 103-113.
	Chyun YS, Raisz LG Stimulation of bone formation by prostaglandin E ₂ <i>Prostaglandins</i> 1984 (27) 97-103.
	Norrdin RW, Jee WSS, High WB The role of prostaglandins in bone in vivo <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> 1999 (41) 139-149.
	Roof SL, deLong MA, Charest RP mRNA expression of prostaglandin receptors EP ₁ , EP ₂ , EP ₃ , and EP ₄ in human osteoblast-like cells and 23 human tissues <i>Journal Bone Min. Res.</i> 1996 (11) S337.
	Hartke JR, Janikowsky ML, deLong MA, Soehner ME, Jee WSS, Lundy MW Prostanoid FP agonists build bone in the ovariectomized rat <i>J. Bone Min. Res.</i> 1999 (14) T326, pg S207.
	Lundy MW, deLong MA, Combs KS, Gross GJ, Soehner ME, Hartke JR Restoration of cancellous architecture and increased bone strength in aged osteopenic rats treated with fluprostenol <i>J. Bone Min. Res.</i> 1999 1(4) SA368, pg S401.
	Wang Y, Woe JA, Dirr MA, Soper DL, deLong MA, Mialing G, De B, Amburgey J, Suchanek E, Taylor CJ The design and synthesis of 13, 14- dihydro prostaglandin F _{2a} analogs as potent and selective ligands for the human FP receptor. <i>J. Med. Chem.</i> 2000 43(5) 945-952.
	Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I, Ushikubi F, Narumiya S, Segi E, Sugimoto Y, Ichikawa A, Nakao K Crucial involvement of the EP ₄ subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide <i>J. Bone and Mineral Research</i> . 2000 15(2) 218-227.

Exp: L. Channarayana

4/17/02

Unable to obtain reference	DeToro F Jr, Sylvia VL, Schutkegel SR, Campos R, Dean DD, Boyan BD, Schwartz Z Characterization of prostaglandin E ₂ receptors and their role in 24,25-(OH) ₂ D ₃ -mediated effects on resting zone chondrocytes <i>J. Cell. Physiol.</i> 2000 182(2) 196-208.
	Narumiya S Roles of prostanoids in health and disease, lessons from receptor-knockout mice <i>Int. Congr. Ser.</i> 1999 1181 261-269
	Audoly LP, Tilley J, Goulet J, Key M, Nguyen M, Stock JL, McNeish JD, Koller BH, Coffman TM Identification of specific EP receptors responsible for the hemodynamic effects of PGE ₂ <i>Am. J. Physiol.</i> 1999 46(3) H824-830.
	Vayssairat M Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis <i>J. Rheumatol.</i> 1999 26(10) 2173-2178.
	Murakami T, Sawada K, Taneda K, Hayashi M, Katsura Y, Tanabe H, Kyoki M, and Araki H. Effect of isocarbocyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease. <i>Arzneim.-Forsch./Drug Res.</i> 1995 45(II) Nr. 9, pg 991-994.
	Hall A, Smith WHT Clinprost Teljin <i>Current Opinion in Cardiovascular, Pulmonary & Renal Investigations Drugs</i> 1999 1(5) 605-610.
	Taneda N, Yamakoshi T, Hasegawa M, Tanikawa H, Nagata H, Maesako KI, Konno A Effect of a thromboxane A ₂ receptor antagonist, ramatroban (BAY U3405), on inflammatory cells, chemical mediators and non-specific nasal hyperreactivity after allergen challenge in patients with perennial allergic rhinitis <i>Allergy International.</i> 1998 47(1), 59-67.
Unable to obtain reference	Miyamoto T, Takahima T A comparison in the efficacy and safety between ramatroban (BAY u 3405) and ozagrel-HCl for bronchial asthma: a phase III, multi-center, randomized, double-blind, group comparative study <i>Rinsho Jyaku.</i> 1997 13 589-639.
	Rampton DS, Carty E, Van Nusten L Anti-inflammatory profile in vitro of ridogrel, a putative new treatment for inflammatory bowel disease <i>Gastroenterology</i> 1999 (116)G3477, pg 801.
	McCullough PA Ridogrel (Janssen) <i>Current Opinion in Anti-inflammatory & Immunomodulatory Investigational Drugs</i> 1999 1(3), 265-278.
	Inoue H Thromboxane A ₂ receptor antagonists <i>Farumashia</i> 1998 32(10) 1221-1225.
	Lardy C, Rousselot C, Chavemac G, Depin JC, Guenier D Antiaggregant and antivasospastic properties of the new thromboxane A ₂ receptor antagonist sodium 4-[[1-[[[4-(4-chlorophenyl) sulfonyl]amino] methyl] cyclopentyl] methyl] benzenesacetate <i>Arzneim.-Forsch./Drug Res.</i> 1994 44(11) 1196-1202.
	Cayatte AJ, Du Y, et al The thromboxane A ₂ receptor antagonist, S18888, decreases atherosclerotic lesions and serum intracellular adhesion molecule-1 in the Apo E knockout mouse <i>Circulation.</i> 1998 98 115.
Unable to obtain reference	Verbeuren TJ, Descombes JJ The TP-receptor antagonist S-18888 unmasks vascular relaxation and potentiates the anti-platelet action of PGD ₂ <i>Thromb. Haemostasis.</i> 1997 693.
Unable to obtain reference	Yoshida K, Sato H Synthesis and pharmacological activities of the new TXA ₂ receptor-antagonist Z-339 and related compounds <i>AFMC</i> 1995 95 53.
	Kerstetter JR, Brubaker RF, Wilson SE, Kullerstrand LJ Prostaglandin F ₂ alpha -1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow <i>American Journal of Ophthalmology</i> 1998 105 30-34.
Unable to obtain reference	AGN-192024 <i>Pharmaprojects</i> Oct. 1998 HB4 S1G.
	VanDenburgh AM, Laibovitz RA, Felix C A one-month dose-response study of AGN 192024, a novel antiglaucoma agent, in patients with elevated intraocular pressure <i>IOVS.</i> 1999 40 (4) 4373-B176, pg S830.

L. Channevayala

4/10/02

	Chen J, Woodward DF, Gil DW, Messier T, Marshall K, Senior J AGN 191129: A neutral prostaglandin F-2 alpha (PGF _{2α}) analog that lacks the mitogenic and uterotonic effects typical of FP receptor agonists <i>IOVS</i> . 1999 40 3562-8420, pg S675.
	Sharil NA, Davis TL, Williams GW ³ H AL-5848 ([³ H]β beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor <i>J. Phar. Pharmacol.</i> 1999 51(6) 885-94.
	Garadi R, Silver L, Landry T, Turner FD Travoprost: A new once-daily dosed prostaglandin for the reduction of elevated intraocular pressure <i>IOVS</i> . 1999 40(4) 4378-8181, pg S831.
	Dean TR, Barnes GE, Li B, Chandler ML Improvement of optic nerve head blood flow after one-week topical treatment with travoprost (AL-06221) in the rabbit <i>IOVS</i> . 1999 40(4) 2888-8563, pg S509
	Griffin BW, Klimko P, Cridder JY, Sharil NA AL-6819: a novel prostaglandin F _{2α} analog with selective antagonist effects at the prostaglandin F _{2α} (FP) receptor <i>J. Pharmacol. Exp. Ther.</i> 1999 280(3) 1278-1284.
	Woodward DF, Bogardus AM, Donello JE, Fairbairn CE, Gil DW, Kedzie KM, Burke JA, Kharlamov A, Rundo E Molecular characterization and ocular hypotensive properties of the prostanoid EP ₂ receptor <i>J. Oc. Pharm. Therap.</i> 1996 11(3) 447-454.
	Karim SMM, Adalgin PG, Kotigoda SR Prostaglandins and human respiratory tract smooth muscle: Structure activity relationship <i>Adv. Prostaglandin Thromboxane Res.</i> 1990 7 989-990.
	Maw GN Pharmacological therapy for the treatment of erectile dysfunction <i>Annu. Rep. Med. Chem.</i> 1999 34 71-80.
	Anon. Alprostadil (named): Alprox-TD, Befar, Femprox, prostaglandin E ₁ (named) <i>Drugs R&D</i> 1999 2(5) 413-414.
Unable to obtain reference	Matsumura H Prostaglandins and sleep <i>Sakshin-No-to Shinkai Kagaku Shiritu</i> 1998 10 79-89.
	Tomita Y, Maeda K, Tagami H Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation <i>Pigm. Cell Res.</i> 1992 5(5, Pt. 2) 367-61.
	Huang A, Katori M, Kawamura M, Li B, Harada Y Different modes of inhibition of increase in cytosolic calcium and aggregation of rabbit platelets by two thromboxane A ₂ antagonists <i>Asia Pacific Journal of Pharmacology</i> 1994 9 163-171
	Fliśiak R, Prokopowicz D Effect of misoprostol on the course of viral hepatitis B <i>Hepato-Gastroenterology</i> 1997 44(17) 1419-1425.
Unable to obtain reference	Mihale D, Cristea E, Mihale D, Cocu F The testing of the hepatoprotective action of some new synthetic prostaglandins <i>Farmacia (Bucharest)</i> 1999 47(5) 43-58.
	Vengerovsky AI, Baturina NO, Saratkov AS Hepatoprotective action of prostaglandins <i>Etap. Klin. Farmakol.</i> 1997 60(5) 78-82.
	Clissold D The potential for prostaglandin pharmaceuticals <i>Spec. Publ. - R. Soc. Chem.</i> 1999 244 115-129.
	Zimbric, M.L.; Cappas, A.A.; Uno, H.; Albert, D.M.; EFFECTS OF LATANOPROST OF HAIR GROWTH IN THE BALD SCALP OF STUMPTAILED MACAQUES. <i>IOVS</i> , 1999 (40) 3569-8427, pg S676
	Voss, N.G.; Lindstrom, M.J.; Zimbric, M.L.; Albert, D.M.; Uno, H INDUCTION OF ANAGEN HAIR GROWTH IN TELOGEN MOUSE SKIN BY TOPICAL LATANOPROST APPLICATION . <i>IOVS</i> , 1999 (40) 3570-8428, pg S676
	Johnstone, M.A Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. <i>American Journal of Ophthalmology</i> 1997 544-547
	Eisenberg DL, Camras CB A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. <i>Drug Safety</i> 1999 20(6), 505-514
	Millican LE, Treatment of Alopecia. <i>Journal Clinical Pharmacology</i> 1987 (27) no. 9, pg 715




L. Chamarajala

4/17/02

	Depperman, W.H. Jr.; Up-to-date scalp tonic. <i>New England Journal of Medicine</i> , (1970 Nov 12) 283 (20) 1115.
	Johnstone MA Brief istanoprost Rx induces hypertrichosis. <i>Int. J. Derm.</i> (March 15, 1998) Vol. 38, No. 4, pg. S258
Unable to obtain reference	Al-Sereiti, M.R.; Abu-Amer, K.M.; Sen, P.; Al-Fateh University of Medical Sciences, Tripoli, Libya, <i>Indian J. Pharmacology of rosemary (rosmarinus officinalis Linn.) and its therapeutic potentials-Exp. Biol.</i> (1998), 37(2), 124-130.
	Olsen EA, and DeLong E. Transdermal viprostol in the treatment of male pattern baldness. <i>Journal of American Acad. Dermatology</i> , (1990) 23 (3 Part 1), 470-472.
	Houssay AB, Arias NH, Davison TA, and Epper CE Effects of prostaglandins upon hair growth in mice. <i>Acta Physiol. Lat. Am.</i> (1976), 28(3), 188-191
	Millan LE Treatment of male pattern baldness. <i>Drug Therapy</i> 1989 19, No. 3, 62-73.
	Roanick HH New topical agents for hair growth. <i>Clinics in Dermatology</i> 1988 6 (4) 119-21.
	Vincent JE Prostaglandin synthesis and selenium deficiency a hypothesis. <i>Prostaglandins</i> , (1974) 8 (4), 339-340
	Malkinson FD, Geng L, and Hanson WR Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin. <i>Journal Invest. Dermatol.</i> (1989) 101 (1, Suppl.), 135e-137a.
	Jimenez JJ, Hussein AM, and Yunis AA Stimulated monocyte-conditioned media protect from cytosine arabinoside-induced alopecia in rat. <i>Clin. Res.</i> (38, No. 4, 973a, (1990)
	Hanson, W.R.; Pelka, A.E.; Nelson, A.K.; and Malkinson, F.D.; Rush Medical Center, Chicago. 16,16 dm prostaglandin 2 protects from acute radiation-induced alopecia in mice. <i>Clin. Res.</i> (38, No. 6, 908a, 1990)
	Ling G, Hanson WR, Malkinson FD, 16,16 dm prostaglandin E2 protects mice from fractionated radiation-induced alopecia. <i>Clin. Res.</i> , 1988 36, No. 6, 906a
Unable to obtain reference	Hanson, W.R.; Geng, L.; and Malkinson, F. D.; Loyola and Hines Medical Centers, Maywood, IL Prostaglandin-induced protection from radiation or doxorubicin is tissue specific in mice. <i>Journal of Investigative Dermatology</i> , (1998) vol. 106, No. 4, pg 858.
	Geng L, Malkinson FD, Hanson WR, Misoprostol, a PGE-1 analog that is radioprotective for murine intestine and hair, induces widely different cytokinetic changes in these tissues. <i>Journal of Investigative Dermatology</i> , (1998) Vol. 106, No. 4, Pg. 858.
	Geng L, Hanson WR, Malkinson FD, Topical or systemic 16,16 dm-prostaglandin E2 or WR-2721 (WR-1085) protects mice and alopecia after fractionated irradiation. <i>Int. Journal Radiat. Biol.</i> (1992), 61(4), 533-7.
	Hanson WR, Pelka AE, Nelson AK, Malkinson FD Subcutaneous or topical administration of 16,16 dimethyl prostaglandin E2 protects from radiation-induced alopecia in mice. <i>Int. Journal Radiat. Oncol., Biol, Phys.</i> (1992), 23(2), 333-7
	Hulan HW, Kramer JKG, The effect of long-chain monoenes on prostaglandin E2 synthesis by rat skin. <i>Lipids</i> (1977), 12(7), 604-9
	Hulan HW, Hunsaker WG, Kramer JKG, Mahadevan S, The development of dermal lesions and alopecia in male rats fed rapeseed oil. <i>Can. J. Physiol Pharmacol.</i> (1976) 54, (1), 1-8.
	Sredni B, Xu RH, et al The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. <i>Int. J. Cancer</i> (1996), 65 (1), 97-103
	Kvedar JC, Baden HP, Topical minoxidil in the treatment of male pattern alopecia. <i>Pharmacotherapy</i> 1987 (7) No. 6, 191-97
	Hecker M; Ullrich,V; Studies on the interaction of minoxidil with prostacyclin synthase in-vitro. <i>Biochem. Pharmacol.</i> , (1988) 37(17), 3363-3365
	Michalet JF, Commo S, Biloni N, Mahe YF, Bernard BA Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulation effect. <i>Journal of Investigative Dermatology</i> (1997), 108(2), 205-209.
	Lachgar S, Charveron M, Bouhaddioui N, Gail Y, Bonafe JL Modulation by minoxidil and VEGF of the production of inflammatory mediators by hair follicle dermal papilla cells. <i>Journal Invest. Dermatol.</i> 1995 104, No. 1, 161
	Lachgar, S. Charveron, M.; et al; Hair dermal papilla cell metabolism is influenced by minoxidil. <i>Fundam. Clin. Pharmacol.</i> 1997 (11, No. 2) 178

L. Channarayana

4/17/02

Unable to obtain reference	Lachgar, S. Charverson, M.; et al; Laboratoire Culture De Peau, Clinical and Bio-Clinical Research Group Dermatology, Toulouse, France. Effect of VEGF and minoxidil on the production of arachidonic acid metabolites by cultured hair, dermal papilla cells. <i>European Journal of Dermatol.</i> (1998), 6(5), 365-368
	Saul JJ, White JG, Wilkop CJ Influence of prostaglandin E-1 prostaglandin E-2 and arachidonate on melanosomes in melanocytes and keratinocytes of anagen bulbs in-vitro. <i>Journal Invest. Dermatol.</i> (1975) 64(5), 332-337
EXAMINER	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	DATE CONSIDERED 

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE